ISRCTN46445413
Completed
Phase 3
Prospective, randomised, double-blind, placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with inflammatory osteoarthritis (OA) of the hands
Charité - University of Medicine, Berlin (Germany)0 sites510 target enrollmentJune 9, 2011
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Refractory inflammatory hand osteoarthritis
- Sponsor
- Charité - University of Medicine, Berlin (Germany)
- Enrollment
- 510
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
2014 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/25348033 protocol
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Men and women from 40 to 80 years
- •2\. Presence of clinical hand OA according to American College of Rheumatology (ACR) criteria
- •3\. Conforming to the ACR criteria for hand OA with recent X ray, dating less than 6 months ago, X ray of the hands showing radiological signs of digital OA in one or more joints as defined by grades 2 or higher, per Kellgren and Lawrence scale or alternatively using the Kallman method or alternativly using the Verbruggen Score;
- •4\. Symptomatic digital OA with more than three finger joints for more than 3 months (at least every other day) despite taking analgesics and non\-steroidal anti\-inflammatory drugs (NSAIDs)
- •5\. Pain above 35 mm as evaluated by the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) \-Visual Analogue Scale( VAS) (0 \- 100 mm)
- •6\. Function as co\-primary clinical outcome with \= 9 using the AUSCAN LK function subscale, or \= 225 F (out of maximum of 800\) on the AUSCAN VA function subscale
Exclusion Criteria
- •1\. Patients who have already been treated with HCQ
- •2\. Existence of painful syndrome of upper limbs likely to interfere with the monitoring of pain
- •3\. Patients suffering or having suffered from secondary OA after one of the following diseases (e.g. infectious arthritis, acromegaly, ochronosis, haemochromatosis, gout, etc.) or inflammatory joint diseases
- •4\. Any unstable medical condition which would put the patient at an unacceptable risk
- •5\. Planned Surgery
- •6\. Local injection with glucocorticoids or other medications within the previous three months
- •7\. Oral glucocorticoids
- •8\. Presence of retinopathy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
SUBpectoral Local anaesthetic Infusion following MastEctomy - version 1 (SUBLIME)ISRCTN46621916Royal Cornwall Hospitals NHS Trust (UK)160
Completed
Not Applicable
A randomised prospective double-blind, placebo controlled trial of prophylactic oral levofloxacin following chemotherapy for lymphoma and solid tumoursBreast, testis, lung (small cell), lymphoma (Hodgkins), lymphoma (non-Hodgkins)CancerComplications of procedures, not elsewhere classifiedISRCTN49693355Cancer Research UK (CRUK) (UK)1,500
Completed
Not Applicable
Effect of Remote Ischaemic preConditioning on contrast medium induced nephropathy (CIN) (ERICCIN)ISRCTN49645414niversity College London (UK)362
Completed
Phase 2
A randomised, double blind, placebo-controlled study of RAD001 (Everolimus) in the treatment of neurocognitive problems in tuberous sclerosisTuberous sclerosisNervous System DiseasesISRCTN09739757Cardiff University (UK)38
Active, not recruiting
Phase 3
Phase 3 trial of exenatide for Parkinson’s diseaseParkinson’s diseaseNervous System DiseasesParkinson diseaseISRCTN14552789niversity College London194